Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Lenalidomide Combined With Rituximab as Front-line Therapy in Elderly Patients Aged Over 80 Years With Diffuse Large B Cell Lymphoma
Authors not listed
Guangdong Provincial People's Hospital · 2020
Abstract
About 40% of Diffuse large B cell lymphoma relapse or is refractory, age is a prognostic factor of DLBCL, as elderly patients are not capable to received standard treatment, the prognosis of elderly patients is poor especially those aged over 80 years. In this study,we aimed to investigate the safety and efficacy of the combination of lenalidomide and rituximab in elderly patients aged ≥ 80 years with untreated DLBCL.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-07 MST
Cite this
APA
Anonymous. (2020). Lenalidomide Combined With Rituximab as Front-line Therapy in Elderly Patients Aged Over 80 Years With Diffuse Large B Cell Lymphoma. <em>Guangdong Provincial People's Hospital</em>. https://clinicaltrials.gov/study/NCT04622579
Vancouver
Anonymous. Lenalidomide Combined With Rituximab as Front-line Therapy in Elderly Patients Aged Over 80 Years With Diffuse Large B Cell Lymphoma. Guangdong Provincial People's Hospital. 2020.
BibTeX
@misc{anon2020Lenali,
title = {Lenalidomide Combined With Rituximab as Front-line Therapy in Elderly Patients Aged Over 80 Years With Diffuse Large B Cell Lymphoma},
author = {Anonymous},
journal = {Guangdong Provincial People's Hospital},
year = {2020},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Lymphoma Study Association 2006
Open access · US-GOV
Phase II Study of Mini-CHOP Plus Rituximab in Non Previously Treated Patients Aged Over 80 Years With CD 20+ Diffuse Large B-Cell Lymphoma
Fondazione Italiana Linfomi - ETS 2003
Open access · US-GOV
A Randomized Phase III Randomized Study to Compare R-CHOP Versus R-mini-CEOP in Elderly Patients (>65 Years) With Diffuse Large B Cell Lymphoma (DLBCL)
The First Affiliated Hospital with Nanjing Medical University 2020
Open access · US-GOV
Efficacy and Safety of Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma
The First Affiliated Hospital of Soochow University 2024
Open access · US-GOV
A Prospective and Exploratory Clinical Study of Pomalidomide, Rituximab and Orelabrutinib Combined With Polatuzumab Vedotin in the Treatment of Newly Diagnosed Elderly Patients With DLBCL
Mingzhi Zhang 2017
Open access · US-GOV
Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University 2012
Open access · US-GOV